Zhang H - Search Results

1

BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.

Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. Yin X, et al. Among authors: zhang h. Int J Cancer. 2010 Mar 1;126(5):1216-25. doi: 10.1002/ijc.24815. Int J Cancer. 2010. PMID: 19662650

2

Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.

Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Yin X, et al. Among authors: zhang l, zhang h. Clin Cancer Res. 2005 May 15;11(10):3889-96. doi: 10.1158/1078-0432.CCR-04-2272. Clin Cancer Res. 2005. PMID: 15897590

3

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ. Lundgren K, et al. Among authors: zhang h. Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758. Mol Cancer Ther. 2009. PMID: 19372565

4

BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.

Zhang H, Neely L, Lundgren K, Yang YC, Lough R, Timple N, Burrows F. Zhang H, et al. Int J Cancer. 2010 Mar 1;126(5):1226-34. doi: 10.1002/ijc.24825. Int J Cancer. 2010. PMID: 19676042

5

Targeting multiple signal transduction pathways through inhibition of Hsp90.

Zhang H, Burrows F. Zhang H, et al. J Mol Med (Berl). 2004 Aug;82(8):488-99. doi: 10.1007/s00109-004-0549-9. Epub 2004 May 27. J Mol Med (Berl). 2004. PMID: 15168026 Review.

6

Hsp90 activation and cell cycle regulation.

Burrows F, Zhang H, Kamal A. Burrows F, et al. Among authors: zhang h. Cell Cycle. 2004 Dec;3(12):1530-6. doi: 10.4161/cc.3.12.1277. Epub 2004 Dec 30. Cell Cycle. 2004. PMID: 15539946 Review.

7

Identification of new biomarkers for clinical trials of Hsp90 inhibitors.

Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F. Zhang H, et al. Among authors: zhang l. Mol Cancer Ther. 2006 May;5(5):1256-64. doi: 10.1158/1535-7163.MCT-05-0537. Mol Cancer Ther. 2006. PMID: 16731758

8

Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.

Zhang H, Yang YC, Zhang L, Fan J, Chung D, Choi D, Grecko R, Timony G, Karjian P, Boehm M, Burrows F. Zhang H, et al. Among authors: zhang l. Int J Cancer. 2007 Feb 15;120(4):918-26. doi: 10.1002/ijc.22392. Int J Cancer. 2007. PMID: 17131314

9

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.

Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F, Zhang H. Dakappagari N, et al. Among authors: zhang h. Biomarkers. 2010 Feb;15(1):31-8. doi: 10.3109/13547500903261347. Biomarkers. 2010. PMID: 19747088

10

Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors.

Moser C, Lang SA, Hackl C, Zhang H, Lundgren K, Hong V, McKenzie A, Weber B, Park JS, Schlitt HJ, Geissler EK, Jung YD, Stoeltzing O. Moser C, et al. Among authors: zhang h. Anticancer Res. 2012 Feb;32(2):427-37. Anticancer Res. 2012. PMID: 22287729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130,575 results

Search Page

Filters